The chemokine stromal cell-derived factor-1 (SDF-1) and its receptor, CXCR4, participate in the retention of acute myeloblastic leukemia (AML) cells within the bone marrow microenvironment and their release into the circulation. AML cells also constitutively express SDF-1-dependent elastase, which regulates their migration and proliferation. To study the molecular events and genes regulated by the SDF-1/CXCR4 axis and elastase in AML cells, we examined gene expression profiles of the AML cell line, U937, under treatment with a neutralizing anti-CXCR4 antibody or elastase inhibitor, as compared with non-treated cells, using DNA microarray technology. Unsupervised hierarchical clustering analysis demonstrated similar gene expression profiles of anti-CXCR4 antibody or elastase inhibitor-treated cells, as compared with control. Pathway and functional analysis showed a greater tendency toward differentiation in cells under either one of both treatment modalities. Thus given, we further analyzed the effects of CXCR4 inhibition on AML cell growth and differentiation using the antagonist AMD3100. AMD3100 arrested proliferation in AML cell lines and triggered changes that mimicked differentiation, including morphological changes and the expression of myeloid differentiation antigens. Inhibition of elastase also triggered the differentiation of AML cells. Our study defines a new role for the SDF-1/CXCR4 axis in the regulation of leukemic cell survival and differentiation.
Introduction
In recent years, a number of studies emphasized the importance of the interactions between the leukemic cells and the bone marrow (BM) microenvironment for the maintenance and progression of acute myeloblastic leukemia (AML). 1, 2 Moreover, the marrow is considered to be the site of origin for minimal residual disease (MRD), as adhesion to BM stroma cells and signaling through their secreted elements induce AML cells resistance to cytotoxic drugs. 3, 4 Marrow-derived stromal cells constitutively secrete the chemokine stromal cell-derived factor-1 (SDF-1) (also named CXCL-12), which is the only chemoattractant for hematopoietic progenitor cells, that is so far proved as significant. 5, 6 In previous studies, our group and others, showed that the SDF-1 and its receptor CXCR4 interaction is essential for both normal and leukemic hematopoietic cell migration in vivo. 7, 8 In transplanted NOD/SCID mice, homing and subsequent engraftment of human normal or AML stem cells are dependent on the expression of cell surface CXCR4 and SDF-1 produced within the murine. [9] [10] [11] [12] In addition to controlling cell motility, SDF-1 regulates cell proliferation, induces cell cycle progression and acts as a survival factor for normal human stem cells and AML cells. [13] [14] [15] [16] CXCR4 blockage in AML cells, using the polypeptide RCP168, enhanced chemotherapy-induced apoptosis in vitro. 17 Most importantly, high CXCR4 expression level in leukemic cells was proved as a predictor of overall survival and relapsefree survival in patients with AML. 18, 19 Although AML cells express variable levels of external CXCR4, high expression of internal CXCR4 is found. Furthermore, both intracellular and cell surface SDF-1 were detected in AML cells, suggesting secretion of this chemokine by the malignant cells. 12 Neutrophil elastase is a serine protease stored in azurophilic granules of myeloid cells and is released upon activation and degranulation. Elastase, among other neutrophil serine proteases, such as proteinase 3 and cathepsin G, is synthesized during the transition of myeloblast to promyelocyte. The role of myeloid serine proteases in the regulation of cell growth was first revealed when membrane extracts from AML cells (named common antigen of myelogenous leukemia, CAMAL), which contain primary granule proteins, such as elastase, cathepsin G, azurocidin and proteinase 3, were shown to inhibit normal hematopoiesis. 20, 21 Bories et al. 22 showed that the inhibition of proteinase 3 expression by an antisense oligodeoxynucleotide inhibits proliferation and induces differentiation of AML cell line. However, the exact role of the proteolytic enzymes, such as elastase, in AML development is yet unstudied. Recently, we found that AML cells constitutively secrete and express SDF-1-dependent cell surface elastase, which regulates their migration and proliferation. 15 To elucidate the molecular events and genes regulated by SDF-1/CXCR4 axis and elastase, we compared global gene expression profiles of AML cells treated with neutralizing CXCR4 monoclonal antibody (mAb) or with elastase inhibitor (EI) with untreated cells, using a DNA microarray technology. We further investigated the effect of inhibition of these pathways on the growth and differentiation of AML cells using in vitro assays and found that inhibition of either CXCR4 or elastase pathway led to decreased cell survival and provoked differentiation of AML cells.
Materials and methods

Microarray analysis
U937 cells were cultured with or without monoclonal anti-CXCR4 antibody (mAb) 12G5 (10 mg/ml, R&D Systems, Minneapolis, MN, USA) or EI MeOSuc-AAPV-CMK (10 mg/ml, Calbiochem, La Jolla, CA, USA) for up to 24 h and total RNA was harvested at different time points. For gene expression analysis, total RNA was biotinylated and hybridized to 8757 probe sets Affymetrix Human Focus oligonucleotide arrays with minor modifications from the manufacturer's recommendations (url2). A list of 4921 'valid' probe sets, representing probe sets with signals higher than 20 and detected as present (P) in at least one sample, was analyzed for hierarchical clustering using Spotfire DecisionSite for functional genomics (Somerville, MA, USA). The comparison generated a list of 295 'active genes' representing probe sets that were changed by at least twofold, as calculated by the MAS 5 log ratio values (LRX1 or LRp1) and detected as 'increase' or 'decrease' (I or D, P-value 0.0025) or as 'marginal increase' or 'marginal decrease' (MI or MD, P-value 0.003) in all treated samples as compared with the control samples. This list excluded genes that were upregulated in all treated samples with signals lower than 20 or detected as absent, and genes that were downregulated with base line signals lower than 20 and detected as absent in the control samples. Genes were classified into functional groups using the GO annotation tool (http://apps1.niaid.nih.gov/david/upload.asp). Calculations of overrepresentation were performed using EASE software (Hosack DA, SAIC Frederick Inc, Frederick, MD). Functional classifications with an 'Ease score' lower than 0.05 were marked as overrepresented. We also compared our gene expression data with profile expression of normal human BM populations at different stages of differentiation. Theilgaard-Monch et al. 25 identified 6700 genes that were differentially regulated by a twofold or more in highly enriched cell populations of promyelocytes (PM), myelocytes/metamyelocytes (MY) and neutrophils (BM-PMN). Out of 17 020 genes analyzed by their microarray, 638 genes were present on our gene chip and could be compared in their expression pattern.
Cell cycle and DNA ploidy analysis HL-60, U937, ML-2, Meg-O1 and CHRF AML cell lines were cultured for 3-11 days in RPMI, supplemented with 10% FCS with or without AMD3100 (10-30 mM; Sigma, St Louis, MI, USA), 9-cis-retinoic acid (1 mM; Sigma) or phorbol-12-myristate 13-acetate (PMA, 10 ng/ml; Sigma). Cell cycle analysis was performed on cells fixed in cold ethanol, stained with 10 mg/ml RNaseA and 0.5 mg/ml propidium iodide (Sigma) and analyzed on a FACS Calibur (Becton Dickinson Immunocytometry System Inc., San Jose, CA, USA) using Cell Quest software.
Caspase 3 activity
Levels of caspase 3 in AML cell lines were quantified by fluorescence spectrometer according to the manufacturer's instructions (Molecular Probes Europe, Leiden, The Netherlands).
Morphology analysis and nitroblue tetrazolium reduction assay
The cellular morphology was studied after Wright-Giemsa staining of cytospin slides. The nitroblue tetrazolium (NBT) assay was performed on a total of 2 Â 10 5 cells suspended in 700 ml RPMI 1640 medium and incubated with 50 mg/ml 12-Otetradecanoyl-phorbol-13-acetate (Sigma) and 0.05% NBT (Sigma) for 30 min at 37 1C. The percentage of cells containing reduced black deposits was determined under a light microscope, by examining 600 cells.
Flow cytometry
Cells were incubated at 4 1C for 30 min with FITC-conjugated mAb to human CD15 (BD Bioscience, San Jose, CA, USA), PECD11b (Dako, Glostrup, Denmark). Isotype-matched control antibodies were used. After staining, cells were analyzed on an FACS Calibur using Cell Quest software.
Quantitative real-time reverse transcription PCR Total RNA isolation was performed using TRI reagent according to the manufacturer's protocol (Molecular Research Center Inc., Cincinnati, OH, USA). RNA of 2 mg was reverse-transcribed with moloney murine leukemia virus reverse transcriptase (M-MLVRT) for 60 min at 42 1C. PCR primers and Universal TaqMan probe 3 were designed using Universal ProbeLibrary Assay Design Center (Roche, Mannheim, Germany). Amplification reactions contained 5 ml diluted cDNA and 12.5 ml Universal TaqMan 2 Â PCR mastermix (Roche); the concentrations of primers and TaqMan probes (sequences will be provided upon request) were 300 and 100 nM, respectively, in a final volume of 12.5 ml. All reactions were performed in triplicates using an iCycler system (Bio-Rad, Hercules, CA, USA) and the thermal cycling conditions were as follows: 10 min at 95 1C followed by 45 cycles at 95 1C for 10 s, 60 1C for 30 s and 72 1C for 1 s. Granulocyte colony-stimulating factor receptor (G-CSFR) gene expression analysis was carried out using the LightCycler-FastStart DNA Master SYBR Green kit (Roche).
Results
Global gene expression of U937 AML cells treated with EI or neutralizing antiCXCR4 mAb compared with non-treated cells
To identify potential SDF-1-and elastase-targeted genes in AML cells, we used Affymetrix Human Focus oligonucleotide arrays. Global gene expressions of U937 AML cells treated with EI for 45 min, 3 h, 6 h and 12 h or neutralizing anti-CXCR4 mAb (12G5) for 6 h, 12 h and 24 h were compared with those of non-treated cells. We choose the U937 cell line because it expresses high levels of CXCR4, its proliferation rate is SDF-1-dependent and it also produces SDF-1. 12 Moreover, U937 cells secrete elastase that regulates both their proliferation and SDF-1-dependent migration. 15 To compile a list of elastase and SDF-1-responsive genes, we singled out genes that were either induced or repressed by at least twofolds after both anti-CXCR4 and EI treatments, at all time points, while compared with non-treated U937 cells. Unsupervised hierarchical clustering analysis demonstrated distinct gene expression profiles for all treated samples as compared with control non-treated sample (Figures 1 and 2 ). Interestingly, gene expression profiles of EI-or anti-CXCR4-treated cells were similar to each other. Out of 8400 genes that were screened, 230 genes were repressed, and 164 were induced after culturing U937 cells in the presence of EI or anti-CXCR4 for all different time periods as compared with non-treated cells. Differentially expressed genes were annotated to gene categories according to their molecular functions using the GO annotation tool and the Ease score for overrepresentation analysis. This annotation revealed that the downregulated genes were assigned to the following major gene categories: metabolism, apoptosis, G2/M transition of mitotic cell cycle, cell proliferation, and response to stress and stimulus (Ease scoreo0.005) (data not shown). A total of 164 genes that were statistically overrepresentative at all time points were grouped as genes involved in defense response and response to Figure 2 Hierarchic clustering analyses of genes that were downregulated after treatment of acute myeloblastic leukemia (AML) cells with anti-CXCR4 monoclonal antibody (mAb) or elastase inhibitor (EI). 'Active' genes that showed more than twofolds change in expression levels in all treated sample as compared with the control sample were classified into functional groups. Red and green colors denote gene expression levels that are either higher or lower than the mean expression level, respectively. CXCR4 regulates AML cell differentiation S Tavor et al CXCR4 axis in U937 AML cells affect similar pathways. Moreover, analysis of the significantly overrepresented genes suggested that both treatments might downregulate the expression of genes that control cell growth and induce expression of genes involved in phagocytosis and defense response.
Selection of functional groups
To further elucidate the molecular mechanisms affected by EI and anti-CXCR4 mAb in AML cells, we classified our 'active' genes into different functional groups. Interestingly, a marked downregulation of the transcripts of human granule proteins, which are present in primary (or azurophil) granules of myeloid precursor cells, was observed after culturing U937 cells in the presence of EI or anti-CXCR4 mAb. The downregulated primary granule proteins included myeloperoxidase, defensin b-1, defensin a-4, cathepsin L, elastase, proteinase 3 and cathepsin G (Supplementary Table 1 ). It can be noted that the downregulation of the transcripts of human primary granule proteins is observed in the process of normal myeloid differentiation, in the transition from PM to myelocytes. 23, 24 Early myeloid differentiation is characterized by the transcription of genes encoding hematopoietic cytokines, chemokines and growth factors. Supplementary Table  1 lists the receptors and their ligands that carried a change of expression of twofolds or more in U937-treated cells at all time points as compared with control. Upregulated cytokines and chemokines included interleukin receptors (IL27RA, IL2RG, IL10RA and IL13RA1) and CX3C chemokine receptors (CX3CR1). The growth factor receptors G-CSFR and granulocyte macrophage colony-stimulating factor (GM-CSF), the receptors for complement component C1q (C1QR1) and immunoglobulin G Fc (FCG1RA) were also upregulated in treated cells. In contrast, FMS-like tyrosine kinase 3 (FLT-3), which is central to myeloid progenitor development, was downregulated in AML cells treated with EI or antiCXCR4 mAb as compared with non-treated cells. Taken together, the observed expression patterns for receptors and ligands suggest a more differentiated cellular phenotype after CXCR4 or elastase inhibition. Many of the downregulated transcriptional factors are overexpressed in AML, and are categorized as being important for the development of leukemia (HOXA9, WT1, HOXA10, ETS2, MLLT10 and ETV6) (Supplementary Table 1 ). On the other hand, transcriptional factors and regulators that are known to be induced during myeloid differentiation, such as C/EBPe, ID1, RUNX3 and HHEX, were upregulated in treated cells. Moreover, the majority of cell cycle regulated genes were downregulated in cells cultured in the presence of EI or neutralizing CXCR4 mAb as compared with control cells, including p53 and p53-dependent genes, such as GADD45A and GADD45B, which are essential for cell cycle check point and DNA repair. To confirm the expression data from the oligonucleotide microarray studies, gene expression in U937 cells cultured with or without EI or 12G5 was analyzed by quantitative real-time reverse transcription PCR. Quantitative realtime reverse transcription PCR for four selected genes, C/EBPe, FLT3, HOXA9 and G-CSFR, demonstrated gene expression profiles identical to the microarray expression profiles (Figure 3 ). Table 1 , genes marked in bold). Although U937 is a monoblastic AML cell line, and can thus be induced to differentiate to the monocytic and not the neutrophilic lineage, these results suggest that inhibition of the SDF-1/CXCR4 axis or elastase regulates similar genes that are involved in the process of differentiation in normal and leukemic cells, implying a role of SDF-1 and elastase in blocking differentiation in AML cells.
AMD3100 inhibits proliferation of AML cells
We have previously shown that inhibition of the SDF-1/CXCR4 axis reduces the proliferation of AML cell lines and the survival of primary AML cells. 12 In line with these results, we now prove that many genes involved in the regulation of cell proliferation were significantly differentially expressed in cells treated with anti-CXCR4 mAb as compared with control cells (Supplementary Table 1 ). To confirm these results, we cultured AML cells with the CXCR4 antagonist AMD3100. Measurements of viable cell fractions over a 9-day period demonstrate that AMD3100 strongly inhibits the growth of five AML cell lines by 40-50% as compared with control at day 5. Thereafter, the number of AMD3100-treated cells rapidly decreased due to cell death at day 7 (in HL60, ML-2, MegO1 and CHRF) and day 9 (in U937 cells) (Figure 4a ). The trypan blue exclusion assay showed that the proportion of dead cells was as high as 90% in AML cells cultured in the presence of AMD3100 for 7-9 days. AMD3100 (Figure 4a ). We further examined the effect of inhibition of the SDF-1/CXCR4 axis on the cell cycle of AML cells. After 7 days of culture in the presence of AMD3100, HL-60 cells showed an increased number of cells (42±9%, Pp0.05) in the sub-G1 phase and a decreased number of cells (32±7%, Pp0.001) in the G0/G1 phase of the cell cycle as compared with control non-treated cells (5 ± 2.5% (sub-G1) and 65±2.8% (G0/G1phase)) (Figure 4b ). Similar changes in cell cycle parameters were observed when ML-2 cells were treated with AMD3100 (data not shown) and when HL60 cells were treated with the differentiating reagents 9-cis RA and PMA (Figure 4b ). It can be noted that treatment of U937 cells with AMD3100 or 9-cis RA did not increase the fraction of cells measured in sub-G1 phase, suggesting non-apoptotic cell death ( Figure 4b ). As in U937 cells, treating Meg-O1 and CHFR cells with AMD3100 increases the fraction of cells measured in S phase and not in sub-G1 phase (data not shown). To examine whether AMD3100 induces apoptosis in AML cells, we analyzed the level of caspase 3 activity. In line with the results of cell cycle analysis, we found a 30-and 8-fold increases in the level of caspase 3 activity after the treatment of HL60 or ML-2 cells for 7 days with AMD3100, respectively (Figure 4c ). In contrast, no increase in the level of caspase 3 activity was observed in AMD3100-treated U937, Meg-O1 or CHFR cells as compared with control non-treated cells (Figure 4c ), implying a non-apoptotic mechanism. Taken together, these results suggest that AMD3100 strongly inhibits the growth of some types of AML cells in a cell-specific mechanism.
Inhibition of CXCR4 or elastase induces differentiation in AML cells
Microarray analysis revealed that inhibition of the SDF-1/CXCR4 axis upregulated genes that are involved in myeloid differentiation. To address the question of whether CXCR4 blockade can trigger differentiation in human AML cells, U937 or HL-60 cells were grown in the presence or absence of AMD3100, EI, 9-cis-RA or PMA for up to 9 days. Cell morphology was examined /ml) were grown in the presence or absence of CXCR4 antagonist (AMD3100 10 mM, 3 times a day), 9-cis RA (1 mM) or PMA (10 ng/ml) for up to 9 days and counted after trypan blue exclusion *Pp0.05, **Pp0.001. (b) HL60 or U937 cells were cultured for 7 days with or without AMD3100, 9-cis RA or PMA, stained with PI and analyzed for cell cycle parameters by flow cytometry. The results represent the average of three independent experiments. (c) Caspase 3 activity was determined with fluorogenic substrate z-DEVD-rhodamine 110 and measured by fluorescence spectrometer. The results represent the mean of three independent experiments. (Figures 5a  and b) . After 9 days in the presence of AMD3100, most of the U937 cells showed a reduction in their nuclear/cytoplasm ratios, displaying a more condensed nuclear chromatin and increased number of cytoplasmic vacuoles, which are morphological characteristics of macrophage-like cells (Figure 5a ). Treated cells displayed an increased expression of the myeloidspecific antigen CD15 (154±21 mean fluorescence intensity (MFI) versus 121 ± 13 in control group P ¼ 0.04) (Figure 5c ). AMD3100 also promotes the ability to produce oxidative bursts in U937 cells as 70.3% of treated cells were NBT þ as compared with 32.5% (Po0.0001) of the control non-treated cells. AMD3100 triggered similar morphological changes in HL60 cells with increased expression of CD11b (15±8% versus 5 ± 7% in control, P ¼ 0.017 in paired t-test) (data not shown), but with no significant change in the number of NBT þ cells (data not shown). EI induced similar cellular changes in HL-60 cells, including reduction in nuclear/cytoplasm ratios, condensation of nuclear chromatin, reducing nucleoli visibility, segmentation of nuclei and granulations (Figure 5b ). These changes were dose-and time-dependent (data not shown). Morphologic evidence of differentiation correlated with the increase in the expression of CD11b cell surface marker that is associated with myeloid differentiation. After 6 days in culture,
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CD11b expression increased from 47 ± 13% to 92 ± 0% (P ¼ 0.002) in HL60 cells cultured in the presence of EI cells (Figure 5d ). In addition, EI induced the ability to produce oxidative bursts, as shown by the presence of 60-90% of NBT þ in treated cells as compared with 10% NBT þ in untreated HL60 cells. Finally, treatment of two megakaryocytic AML cell lines (MegO1 and CHRF) with AMD3100 induced their maturation. The AMD3100-treated cells were larger with lower nuclear/ cytoplasm ratio and had increased number of multinuclear cells (data is not shown). After 8 days in the presence of AMD3100, Meg-O1 and CHRF cells showed a significant increase in the percentage of 4N and decrease in the percentage of 2N DNA content (Figure 5e ).
Discussion
Although 70-80% of AML patients respond to chemotherapy and reach complete remission, disease-free survival is achieved in only 40% of these patients, mainly due to relapses, urging for the development of additional therapies. 26 Recently, a number of studies emphasized the idea that leukemic stem cell compartment is responsible for relapse and the evolution of resistance to chemotherapy. 27 The direct contact relations of leukemic stem cells with the BM microenvironment, known as the stem cell niche, have an important function in their abilities of selfrenewal, survival and undergoing differentiation. Thus, for example, the adhesion molecule CD44 has been found crucial for AML cell development. 28, 29 Other key players in mediating this interaction are the chemokine SDF-1 and its receptor CXCR4. Human AML cells vary in their surface CXCR4 expression levels, but were all found to express high level of intracellular CXCR4 and SDF-1.
12, 30 We have shown that a neutralization treatment that targets CXCR4 leads to the inhibition of repopulation and reduction in survival of human AML cells after engraftmentt in NOD/SCID mice. This effect was considerably more significant in the leukemic stem cell compartment than in the normal human stem cell compartment, suggesting a potential therapeutic function for CXCR4 neutralization in AML. 12 Similarly, high level of CXCR4 expression in AML patients was found to be a factor of poor prognosis. 12, 30, 31 We also showed that the expression of cell surface elastase in AML cells is dependent on the SDF-1/CXCR4 axis, giving a first evidence for an important association between the SDF-1 and elastase pathways.
In this study, we hypothesized that the inhibition of the SDF-1/ CXCR4 axis or elastase may regulate similar pathways and genes in AML cells. To test our hypothesis, we compared gene expression profiles of U937 AML cells that express high level of membrane CXCR4, 12 treated with neutralizing CXCR4 mAb or, with non-treated cells, by using gene array technology. Analysis of the 364 genes that were differentially expressed in both anti-CXCR4 mAb or EI-treated cells under both treatment agents identified genes that correspond with the transcriptional profiles of differentiated myeloid cells in a significantly high prevalence. In normal myelopoiesis, subsets of neutrophilic granule proteins are synthesized simultaneously at different stages of cell maturation. The 'primary granule proteins' are acquired at the myeloblast through the promyelocytic stage; their expression is reduced concomitantly with maturation and the generation of secondary and tertiary granules. 23, 24 It can be noted that the coordinated decrease in the expression of primary granule protein transcripts was shown earlier to occur during the terminal differentiation of normal myeloid. 23, 32, 33 Differentiation agents, such as all-trans retinoic acid or PMA, which induce morphological changes characteristic of mature cells in AML cell lines in vitro, were also shown to inhibit the transcription of primary granule proteins, such as proteinase 3, Cathepsin G and elastase. [32] [33] [34] The currently presented microarray data demonstrate a transcriptional repression of many primary granule proteins induced in U937 cells after treatment of up to 24 h with anti-CXCR4 mAb or EI. This suggests that inhibition of the SDF-1/CXCR4 axis or of the elastase pathway promotes AML transition from arresting at an early stage of myeloid differentiation toward further maturation. The hypothesis is also supported by our microarray data analysis that shows upregulation of the cytokines G-CSF and GM-CSF, which support terminal myeloid differentiation and upregulation of the receptors for complement component C1Q (C1QR1) and the Fc fraction of the immunoglobulin G (FCG1RA). These components enhance phagocytosis and the recognition of immunoglobulins in mature myeloid cells. In addition, the expression of FLT-3, a growth factor receptor that stimulates the growth of early progenitor cells and AML blasts, was downregulated under treatment. As transcription factors are the final common pathway that drives differentiation, the expression pattern of transcription factors, such as C/EBPe, ID1, RUNX3 and HHEX, in treated cells also reflects a more differentiated phenotype. Our microarray analysis indicated that AML cells underwent differentiation when CXCR4 or elastase functions were inhibited. Therefore, we sought to confirm that CXCR4 inhibition in vitro could indeed trigger differentiation of AML cells. Cell differentiation was demonstrated by the following: (1) modifications in cell morphology, (2) increased expression of myeloid differentiation antigens, (3) acquisition of oxydoreduction functions and (4) an increase in DNA ploidy in megakaryoblasts. Cells were treated with 30 mM AMD3100, given in split doses every 5 h, three times a day. This dose of AMD3100 induced massive cell death in all five human AML cell lines tested after 7-9 days of incubation. Interestingly, we observed that CXCR4 blockade differently affected the different types of AML cells that were tested. AMD3100-treated HL60 or ML-2 cells displayed features of apoptosis with an increased number of cells at the sub-G1 phase of the cell cycle, and increased activity of caspase 3. AMD3100 induced cell death in U937, Meg-O1 or CHRF cells as well, yet in these cells it was not through apoptosis. The different effect might be explained by the different states of maturation in which the cells are arrested. Interestingly, Liesveld et al. 35 have recently found that although AMD3100 inhibited the growth of leukemia colony-forming unit, it did not affect proliferation or survival of AML cells in short-term cultures. These data suggest that treatment of AMD3100 preferentially targets undifferentiated progenitor leukemic cells. It can be noted that the dose of AMD3100 used in this study was lower than the dose used in this study, which might explain the discrepancies observed on AML cell survival. To conclude, this study supports the notion that elastase, among other proteolytic enzymes, promotes proliferation of AML cells and inhibits their differentiation, therefore favoring leukemic transformation. We have shown, for the first time, that AMD3100 promotes differentiation of human AML cell lines and decreases their survival. The current data demonstrate not only that the SDF-1/CXCR4 interaction controls migration and homing of AML cells into the BM but that it also regulates their survival and differentiation. Most significantly, our results show that AMD3100 exerts its effects differently depending on the cell type. As AML is a heterogeneous disease, a more extensive study on several types of primary AML cells will be needed to demonstrate the potential therapeutic approach of CXCR4 neutralization in AML.
